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Abstract Nutrigenomics is the science of analyzing and
understanding gene–nutrient interactions, which because of
the genetic heterogeneity, varying degrees of interaction
among gene products, and the environmental diversity is a
complex science. Although much knowledge of human
diversity has been accumulated, estimates suggest that
*90% of genetic variation has not yet been characterized.
Identification of the DNA sequence variants that contribute
to nutrition-related disease risk is essential for developing a
better understanding of the complex causes of disease in
humans, including nutrition-related disease. The Human
Variome Project (HVP; http://www.humanvariomeproject.
org/) is an international effort to systematically identify
genes, their mutations, and their variants associated with
phenotypic variability and indications of human disease or
phenotype. Since nutrigenomic research uses genetic
information in the design and analysis of experiments, the
HVP is an essential collaborator for ongoing studies of
gene–nutrient interactions. With the advent of next gener-
ation sequencing methodologies and the understanding of
the undiscovered variation in human genomes, the nutri-
genomic community will be generating novel sequence
data and results. The guidelines and practices of the HVP
can guide and harmonize these efforts.
Keywords Nutrigenomics  Human Variome Project 
Harmonization
Introduction
Nutrigenomics has been called a ‘‘post-genome’’ field of
research (e.g., [35]) because it could only develop in a
meaningful way after the completion of the sequencing of
the human genome. Ideally, nutrigenomics experiments are
to be designed, conducted, and analyzed with specific
knowledge of genes involved in nutrient metabolism and
physiological processes. Data from the Human Genome
project and subsequent haplotype mapping projects [14,
59–61, 70] demonstrated that any two humans will differ
by 3–5 million bases. However, ongoing re-sequencing of
individual genomes has now identified *18 million single
nucleotide polymorphisms [4, 29, 47]. More recent studies
have also shown structural variation in the human genome
indicating that approximately 13% of the variation between
humans may be due to copy number [1, 31, 41, 50, 68, 71].
The ongoing discovery of new SNPs and structural variants
shows that the genomic era is far from ending, particularly
since the next generation sequencing technologies [42] will
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soon allow for complete analyses of all coding sequences
(i.e., the exome) of all individuals in a research study (e.g.,
[9]) or even for the complete sequencing of individual
genes, including the regulatory regions.
The catalog of genetic variation is being done by the
HapMap and 1,000 Genomes [37, 55] projects. While these
projects are providing fundamental information about
human genetic variation, they are by design limited by (i)
the populations analyzed, (ii) the goal of characterizing
variants that are greater than 1% in the population, and (iii)
they are unlinked to phenotype. The HapMap project [14,
61] analyzed 45 Han Chinese in China, 45 Japanese in
Tokyo, 90 Africans in the Yoruba tribe of Nigeria, and 90
Europeans of Northern European origin. The recently
released HapMap3 data [2] extended the analyses to almost
700 individuals but found that 77% of the SNPs analyzed
in their study had not been previously characterized. The
goal of the 1,000 Genomes project is to analyze *2,000
individuals from 23 populations (Table 1). Due to these
sample sizes, the diversity projects will only be able to
detect variants that are greater than *1% in the popula-
tions tested; some rare variants [39] are found during
targeted re-sequencing that occurs in these projects yet
variation in the many populations not analyzed will not be
found. Rare variants are increasingly suspected of being
involved in healthy and disease phenotypes [12]. Finally,
the goal of these projects is simply to catalog the variants
for future use in research linking genotype to phenotype,
although some phenotype data are available to research in
the consortium. Both HVP and NuGO (Nutrigenomics
Organization) aim to document variation causing pheno-
typic changes such as disease and good health.
The Human Variome Project
The Human Variome Project (HVP; http://www.human
variomeproject.org/) is an international effort to systemat-
ically identify genes, their mutations, and their variants
associated with phenotypic variability and indications of
human disease or phenotype [15, 16, 33, 51]. The goal of
the HVP is to link clinical, medical, and research labora-
tories for developing knowledge. This knowledge will be
accessible to the research and medical communities to
improve research strategies and clinical medical practice.
One of the key deliverables of the HVP is the creation of a
cyber infrastructure to link locus-specific databases
(LSDBs [27]). These databases have similar architecture,
ontologies, and data elements allowing for interoperability
and are curated by local experts. Over 700 LSDBs are






CHB Han Chinese Han Chinese in Beijing, China
CHS Southern Han Chinese Han Chinese south
CDX Dai Chinese Chinese Dai in Xishuangbanna, China
CHD Denver Chinese Chinese in Denver, Colorado (pilot 3 only)
JPT Japanese Japanese in Tokyo, Japan
KHV Kinh Vietnamese Kinh in Ho Chi Minh City, Vietnam
CEU CEPH Utah residents (CEPH) with Northern and
Western European ancestry
TSI Tuscan Toscani in Italia
GBR British British in England and Scotland
FIN Finnish Finnish in Finland
IBS Spanish Iberian populations in Spain
YRI Yoruba Yoruba in Ibadan, Nigeria
LWK Luhya Luhya in Webuye, Kenya
GWD Gambian Gambian in Western Division, The Gambia
GHN Ghanaian Ghanaian in Navrongo, Ghana
MAB Malawian Malawian in Blantyre, Malawi
ASW African–American SW African Ancestry in Southwest US
AJM African–American MS African American in Jackson, Mississippi
ACB African–Caribbean African Caribbean in Barbados
MXL Mexican–American Mexican Ancestry in Los Angeles, California
CLM Colombian Colombian in Medellin, Colombia
PEL Peruvian Peruvian in Lima, Peru
PUR Puerto Rican Puerto Rican in Puerto Rico
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maintained across the world and accessible at the Human
Genome Variation Society website (http://www.hgvs.org/
dblist/glsdb.html). Some, but not all, of the information in
LSDBs are consolidated in national and international dat-
abases such as at the National Center for Biotechnology
Information (NCBI—http://www.ncbi.nlm.nih.gov/) and
the European Bioinformatics Institute (EBI—http://www.
ebi.ac.uk/).
The HVP has 10 key objectives (Fig. 1):
1. Capture and archive all human gene variation associ-
ated with human disease in a central location with
mirror sites in other countries. Data governance will
ensure security and integrity through the use of auditing
and security technologies but nevertheless allow
searching across all genes using a common interface.
2. Provide a standardized system of gene variation
nomenclature, reference sequences, and support
systems that will enable diagnostic laboratories to
use and contribute to total human variation knowledge.
3. Establish systems that ensure adequate curation of
human variation knowledge from gene-specific
(locus-specific), country-specific, or disease-specific
database perspective to improve accuracy, reduce
errors, and develop a comprehensive data set com-
prising all human genes.
4. Facilitate the development of software to collect and
exchange human variation data in a federation of
gene-specific (locus-specific), country-specific, dis-
ease-specific, and general databases.
5. Establish a structured and tiered mechanism that
clinicians can use to determine the health outcomes
associated with genetic variation. This will work as a
dialog between those who use human variation data
and those who provide them. Clinicians will be
Fig. 1 The key goals of the Human Variome Project and Nutrigenomic Organization (NuGO). Data from nutrigenomics’ experiments are from
research, population, and clinical studies. See text for details
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encouraged to provide data and will have open access
to complete variation data.
6. Create a support system for research laboratories that
provides for the collection of genotypic and pheno-
typic data together using the defined reference
sequence in a free, unrestricted, and open access
system and create a simple mechanism for logging
discoveries.
7. Develop ethical standards to ensure open access to all
human variation data that are to be used for global
public good and address the needs of ‘‘indigenous’’
communities under the threat of dilution in emerging
countries.
8. Provide support to developing countries to build
capacity and to fully participate in the collection,
analysis, and sharing of genetic variation information.
9. Establish a communication and education program to
collect and spread knowledge related to human
variation knowledge to all countries of the world.
10. Continue to carry out research within the opportuni-
ties presented by the investigation of human genetic
variation and to present these findings to users of this
information for the benefit of all.
The Nutrigenomics Organization (NuGO)
NuGO was established as an association of 23 universities
and research institutes focusing on jointly developing the
exiting research area of nutrigenomics and nutritional
systems biology. NuGO evolved from an EU Sixth
Framework Network of Excellence and has now transi-
tioned into a global association encompassing individuals
and institutions around the globe.
NuGO has two major objectives:
1. stimulating developments in nutrigenomics, nutrige-
netics, and nutritional systems biology and incorpo-
rating these aspects in nutrition and health research, by
joint research projects, conferences, workshops, and
training. As a legal, nonprofit entity, NuGO can join as
partner in research projects anywhere in the world.
2. shaping the nutrition bioinformatics infrastructure, by
initiating, coordinating, facilitating projects in this area
and by hosting and disseminating all data, results and
information in this area.
The common goals of nutrigenomic community
and the Human Variome Project
The HVP established committees to develop action plans to
meet the 10 key objectives, which overlap or parallel the
goals described in a consensus statement authored by 89
international scientists in the nutrigenomics community
[34], which was co-authored by the members of NuGO.
The parallel objectives of the HVP and NuGO are the
common grounds upon which the two scientific commu-
nities base their interaction, as schematically described in
Fig. 1.
The HVP captures and classifies genetic variation from
voluntary contributions from unlinked clinical, research,
diagnostic, and service laboratories. The nutrigenomic
community had not specifically designated the identifica-
tion and characterization of variation as a goal, even
though many researchers interested in nutrient–phenotype
associations use that knowledge in their experiments (e.g.,
[45, 56]). The emerging consensus that rare polymorphisms
(i.e.,\1% in the population) and copy number variants [46]
may influence health, disease, and nutrient–gene interac-
tions makes it imperative that nutrigenomic researchers
adopt and use sequence technologies and methods as a part
of their experimental design and procedures.
Assessment of pathogenicity—the phenotype
Deleterious gene–phenotype associations are described as
pathogenicity in clinical settings and are described by
genetic, clinical phenotype, and pathology. Basic
researchers use the term deep phenotyping [63] when
analyzing large numbers of genes, metabolites, proteins, or
transcripts, or combinations of omic technologies. These
methodologies are being adopted to the clinic for assess-
ments (e.g., [24, 57]) and have led to the application of
interdisciplinary, primary care, community-based, and
translational research [25, 40, 69] to health and disease
studies, blurring the distinction between basic and clinical
research [9].
Databases
Data transfer, integration, and access are among the major
challenges facing the biomedical researcher in the 21st
century. The abstracts for over 19 million are available in
PubMed in the U.S. National Library of Medicine’s data-
base of publications. Inclusion of quantitative measures of
genetic and environmental variations would likely influ-
ence the results of many of these studies. However, only a
small fraction of full texts and additional data for these
publications is electronically accessible. Moreover, much
of these data are discipline specific, making it a challenge
to mine public-domain results for linked data or knowl-
edge. The HVP is developing standards with international
databases (NCBI and EBI) and projects (e.g., European
Union Gen2Phen initiative—http://www.gen2phen.org).
The nutrigenomic community faces a greater challenge
278 Genes Nutr (2010) 5:275–283
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since few tools or databases are available for nutrition-
related research [58]. Two related initiatives are underway
to address these limitations. The Nutrigenomics Organi-
zation has begun the development of a nutritional pheno-
type database (dbNP—[64]), a research and collaboration
tool, and knowledge base which will allow access to pub-
lically available data. A separate yet key component of
dbNP is WikiPathways [36, 48], an open, collaborative
platform for the curation of biological pathways (http://
www.wikipathways.org) based on all data available to the
curator.
Emerging countries
About 90% of known SNPs are shared between Asians,
Europeans, and Africans and the remaining polymor-
phisms, called private SNPs, are distributed among these
populations [26, 30]. The recent sequencing of the gen-
omes of several individuals (e.g., [5, 38, 66, 67]), along
with gene-specific re-sequencing efforts suggest that a
larger number of SNPs than previously determined, as well
as other sequence variation, exist in the human population.
Estimates from African genetic diversity and the Pan Asian
SNP initiative indicate that 80 to 90% of human genomic
variation resides in the world’s emerging countries. The
Population Reference Sample (POPRES [44]) targets
populations not previously included in the HapMap project,
similar to the 1,000 Genomes initiative. The main focus of
the HVP effort is the inclusion and analyses of clinical
samples from diverse ethnic groups. One of the advantages
of including some ethnic populations is the opportunity to
study genetic diseases due to consanguinity, large family
size, and potential founder effects (e.g., [10, 11, 52]).
Although nutrigenomic researchers do not necessarily
include such populations, unique genetic groups may yield
valuable insights into understanding the distribution of
gene–nutrient interactions in health and disease processes
[32].
Biomedical research has not typically been the focus of
resource for poor countries, even though such activities are
likely to produce economic and health benefits for all [20,
54]. The recently announced global alliance for chronic
disease (GACD—[19]) addresses the increasing consensus
that emerging economies face not only malnutrition but
also the development of chronic diseases, a double eco-
nomic and health burden. Education of health care pro-
viders, the public, and government officials is needed for
demonstrating the universal nature of the HVP’s and
NuGO’s research efforts, the need to include populations in
developing countries, and the benefits from cooperating in
biomedical research ([8, 13, 53, 62].
The NIH National Center for Minority Health and
Health Disparities (NCMHD) recently called for a
paradigm shift to include minority, low socioeconomic and
rural populations, and individuals in biomedical research
[21, 22]. From the perspective of the science underlying
both the HVP and nutrigenomic research efforts, under-
standing the full spectrum of genetic or metabolic spectra
will not be possible without the involvement of all ances-
tral groups. Including these populations and individuals
may allow for a more rapid translation of basic science to
society. Community-based participatory research collabo-
rations may provide forums for addressing cultural and
ethical concerns of biomedical research [40]. The genomic
sovereignty/equality for all countries to be involved in their
research efforts is an accepted norm of the HVP and
nutrigenomic research communities. The value of ‘human
capital’ within all populations is acknowledged and trea-
sured. Real and tangible benefits of biomedical research to
improve health will be generated for participating popu-
lations; the voluntary participation of the greatest number
of countries would ensure targeted interventions to
improve personal and public health.
Ethics
HVP and nutrigenomic researchers are committed to
adhering to the highest ethical principles governing
research, data sharing, and ultimately enabling this new
knowledge to benefit all of the humanity. Ethical guide-
lines specifically for LSDBs were previously published
[17], and new guidelines are in process [49]. NuGO has
also published bioethical guidelines [6, 7]. The ethics of
international health research continue to evolve with a
greater emphasis on development and social justice [28],
values which are consistent with the stated goals of the
HVP and nutrigenomics researchers [34, 51].
A key ethical concern for the Human Variome Project
and eventually for data generated from individuals in
nutrigenomics research is the accessibility of research data
on public websites. For HVP, rare mutations in a popula-
tion open the possibility of identifying the research par-
ticipant. For both fields of research, polygenic analyses
(e.g., whole genome scans) have yielded the identification
of single participants in research studies. Such polygenic
analyses generate data that could be used for re-identifying
individual patients [18] but is less likely in single gene
diseases.
The HVP is developing an ethics review committee with
a subcommittee focused on issues related to LSDB for (i)
providing counsel when dilemmas arise, (ii) overseeing
guidelines, (iii) identifying best practices, (iv) determining
how best to ensure privacy in all situations, (v) formulating
how to handle data for which explicit consent does not
exist or is not possible to achieve, and (vi) developing a
consent form that is consistent for all LSDBs but which can
Genes Nutr (2010) 5:275–283 279
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be adapted to the requirements of individual countries.
NuGO has an ethics committee, and several members are
also members of the HVP ethics group.
Funding and governance
International collaborations of the scope of the HVP and
nutrigenomics efforts are rarely funded. Rather, both orga-
nizations believe that distributed financing for distributed
science is more likely to occur. To make a distributive model
feasible, best practices and harmonized protocols are neces-
sary. The HVP is developing the standards for LSDB’s and
reporting, and NuGO has a rich tradition of developing stan-
dard operating procedures for methodologies (http://
www.nugo.org/sops). Several international efforts are cur-
rently being designed for type 2 diabetes and micronutrient
genomics [65]. Guidelines and policies of the HVP will be
adopted for both of these protocols since both require anal-
yses of phenotype based on genetic differences in study
participants. The HVP is managed by the Genomic Disorders
Research Center (Melbourne, Australia; http://www.
genomic.unimelb.edu.au), and NuGO has a coordinating
council consisting of European scientists from member
Institutions.
Attribution and publication
Large scale science requires novel approaches for attribut-
ing contributions. High throughput technologies generate a
large number of raw data whose availability represents a
great advantage to all scientists working in the field. These
data sets are often unpublished and made available to all
through deposition in public databases. This creates the
need to define new criteria for the attribution of unpublished
data and requires a policy of credits and incentives to be
coordinated between database curators and the editors of
scientific journals. For the nutrigenomics projects, harmo-
nized, distributive funding allows for the publication of
local studies, and the possibility of comprehensive analyses
of all data by a team consisting of individuals from multiple
disciplines and regions. The HapMap project and other
international projects have previously developed proce-
dures for publication credit. The HVP faces additional
challenges since clinics and service laboratories describe
pathogenicity and genetic variation, but academic incen-
tives to publish are not paramount for these professions.
Novel approaches for attribution have been proposed [23,
33, 43] and are starting to be applied by some databases and
continue to be developed by the HVP. A public debate is
also in progress among the editors of genetics journals to
coordinate efforts toward the attribution of data deposition
and database linking (http://www.gen2phen.org/wiki/hvp-
publication-credit-and-incentives-recommendations).
Connecting the projects
Members of the HVP and nutrigenomics community have
attended conferences and workshops, including the 3rd
Asia Pacific Nutrigenomics conference (Melbourne, 2008),
the Fifth China Health Annual for the announcement of the
HVP node in Beijing (2008), the Symposium of Princess
Al-Jawhara Center of Excellence in Research of Hereditary
Disorders (King Abdulaziz University. Jeddah, Saudi
Arabia), the Third HVP planning meeting (Costa Brava,
Spain) and at the Fourth HVP meeting (Roadmap: Project
structure) at UNESCO (Paris, France). NuGO organized a
micronutrient genomics workshop at the UNESCO meet-
ing. Future meetings include co-hosting workshops at the
International Conference on Nutrigenomics (ICON) in
Guaruja’, Brazil (September 2010). The HVP and NuGO
are exploring the best means to formally recognize their
ongoing interactions. The HVP has a similar ongoing
relationship with the International Society for Gatrointes-
tinal Hereditary Tumors (http://www.insight-group.org).
Organisms are complex systems that are regulated by
interactions between multiple environmental factors and
multiple genes. Analyzing complex systems requires a
multidisciplinary and multi-technological approach (i.e.,
omics). Since each person or team has a limited level of
complexity, the ideal, and indeed, the only, approach to
understand biological systems is to distribute the task
among many teams (see [3]). The interaction between the
HVP and nutrigenomics researchers leverages the expertise
of both groups and fosters a more complete analysis of the
human organism. These articles will assist the process of
populating the human genome sequence with variations
which are biologically and medically relevant and even-
tually provide the complete ‘‘human variome.’’
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